Uric acid and renal disease

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 9-11, 2006, Pages 1055-1064

  Cameron, J Stewart ^a,b  

^a GUY S HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Hyperuricaemia; Renal disease; Tumor lysis syndrome; Urate nephropathy; Uric acid; Uric acid stones

Indexed keywords

ALLOPURINOL; OXONIC ACID; PURINE; TOXIN; URATE; URIC ACID;

ACUTE DISEASE; ALKALINIZATION; ANION EXCHANGE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; GLOMERULUS; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY PARENCHYMA; MAMMAL; NONHUMAN; SCAR FORMATION; TUMOR CELL DESTRUCTION; URIC ACID NEPHROPATHY; URIC ACID STONE;

HUMANS; HYPERURICEMIA; KIDNEY; KIDNEY CALCULI; KIDNEY DISEASES; KIDNEY GLOMERULUS; MODELS, BIOLOGICAL; TUMOR LYSIS SYNDROME; URIC ACID;

EID: 33750472732     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770600890954     Document Type: Article

References (55)

1. Johnson, R.J.; Cameron, J.S. (Eds) Uric acid in cardiovascular and renal disease. Seminars in Nephrology 2005, 25, 1-166.
2. Cameron, J.S.; Simmonds, H.A. Hereditary hyperuricemia and renal disease. Seminars in Nephrology, 2005, 25, 9-18.
3. Cameron, J.S.; Simmonds, J.S. Uric acid and the kidney. In Oxford Textbook of Clinical Nephrology, 3rd edition. Davison, A., Cameron, J.S., Grünfeld, J.P. et al. (Eds.) Oxford University Press, Oxford, 2005, vol 2, pp. 1059-1073.
4. Weiner, I. Urate transport in the nephron. Am. J. Physiol. 1979, 237, F85-F92.
5. Diamond, H.S. Interpretation of pharmacologic manipulation of urate transport in man. Nephron 1989, 51, 1-5.
6. Rafey, M.A.; Lipkowitz, M.S.; Leal-Pinto, E.; Abramson, R.G. Uric acid transport. Current Opinion in Nephrology and Hypertension 2003, 12, 511-516.
7. Enomoto, A.; Kimura, H.; Chairongdua, A.; Shigeta, Y.; Jutabha, P.; Cha, S.H.; Hosyamada, M.; Takeda, M.; Sekine, T.; Igarashi, T.; Matsuo, H.; Kikuchi, Y.; Oda, T.; Ichida, K.; Hosoya, T.; Shimokata, K.; Niwa, T.; Kanai, Y.; Endou, H. Molecular identification of a renal urate-anion exchanger that regulates bood urate levels. Nature 2002, 417, 447-452.
8. Roch-Ramel, F.; Guisan, B.; Diezi, J. Effect of uricosuric and anti-uricosuric agents on urate transport in human brush-border membrane vesicles. Journal of Experimental Pharmacology and Therapeutics 1997, 280, 839-845.
9. Sekine, T.; Cha, S.H.; Endou, H. The multispecific organic ion transporter (OAT) family. European Journal of Physiology 2000, 440, 337-350.
10. Jutabha, P.; Kanai, Y.; Hosoyamada, M.; Chairongdua, A.; Kim do, K.; Iribe, Y.; Babu, E.; Kim, J.Y.; Anzai, N. Identification of a novel voltage-driven organ ion transporter present at apical membrane of renal proximal tubule. Journal of Biological Chemistry 2003, 278, 27930-27938.
11. Lipkowitz, M.S.; Leal-Pinto, E.; Cohen, B.E.; Abramson, R.G. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconjugate Journal 2004, 19, 491-498.
12. Hagos, Y.; Stein, D.; Ugele, B.; Burckhardt, G.; Bahn, A. Human renal organic ion transporter 4 (hOAT4) operates as an asymmetrical organic ion /OH' or anion Cl' exchanger. Kidney and Blood Pressure Research 2004, 27, 267-423.
13. Van Aubel, R.A.; Smeets, P.H.; van den Heuvel, J.J.; Russel, F.G. Human organic ion transporter MRP4 (ABCC4) is an efflux pump for the urine end metabolite urate with multiple allosteric binding sites. Am. J. Physiol.- Renal Fluid Electrolyte Physiol. 2005, 288, F327-F333.
14. Kooij, A.; Schijns, M.; Fredricks, W.M.; Van Noorden, C.J.; James, J. Distribution of xanthine oxidoreductase activity in human tissues-a histochemical and biochemical study. Virchows Archiv, B.; Cell Pathology including Molecular Pathology 1992, 63, 17-23.
15. Kramer, H.J.; Choi, H.K.; Atkinson, K.; Stampfer, M.; Curhan, G.C. The association between gout and nephrolithiasis in men: the Health Professionals' follow-up study. Kidney International 2003, 64, 1022-1026.
16. Kamel, K.S.; Cheema-Dhadli, S.; Halperin, M.L. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney International 2002, 61, 988-994.
17. Sakhaee, K.; Adams-Huet, B.; Moe, O.W.; Pak, C.Y.K. Pathophysiologic basis for normouricsuric acid nephrolithiasis. Kidney International 2002, 62, 971-979.
18. Mohr, P. Urate deposition in tissues. In Urate Deposition in Man and its Clinical Consequences. Gresser, U. and Zöllner, N. (Ed.), Springer-Verlag, Berlin 1991, pp. 24-27.
19. Talbott, J.H.; Terplan, K.L. The kidney in gout. Medicine (Baltimore) 1960, 39, 405-467.
20. Barlow, K.A.; Beilin, L.J. Renal disease in primary gout. Quarterly Journal of Medicine 1968, 37, 79-96.
21. Beck, L.H. Requiem for gouty nephropathy. Kidney International 1986, 30, 280-287.
22. Nickeleit, V.; Mihatsch, M.J. Uric acid nephropathy and end stage renal disease- review of a nondisease. Nephrology Dialysis Transplantation 1997, 12, 1832-1838.
23. Ifudu, O.; Tan, C.C.; Dulin, A.L.; Delano, B.G.; Friedman, E.A. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. American Journal of Kidney Diseases 1994, 23, 347-351.
24. Berger, L.; Yu, T.-F. Renal function in gout. IV An analysis of 524 gouty subjects including long-term follow-up studies. American Journal of Medicine 1975, 59, 695-613.
25. Gibson, T.; Highton, J.; Potter, C.; Simmonds, H.A. Renal impairment and gout. Annals of the Rheumatic Diseases 1980, 39, 417-423.
26. Jones, D.P.; Mahmoud, H.; Chesney, R.W. Tumor lysis syndrome: pathogenesis and management. Pediatric Nephrology 1995, 9, 206-212.
27. Cannon, P.J.; Symchych, P.S.; Demartini, F.E. The distribution of urate in human and primate kidney. Proceedings of the Society for Experimental Biology and Medicine 1968, 129, 278-284.
28. Emmerson, B.T.; Row, P.G. An evaluation of the pathogenesis of the gouty kidney. Kidney International 1975, 8, 65-71.
29. Brown, J.; Mallory, G.K. Renal changes in gout. New England Journal of Medicine 1950, 243, 325-329.
30. Farebrother, D.A.; Hatfield, P.; Simmonds, H.A.; Cameron, J.S.; Jones, A.S.; Cadenhead, A. Experimental crystal nephropathy (one year study in the pig). Clinical Nephrology 1975, 4, 243-250.
31. Potaux, L.; Aparicio, M.; Maurel, C.; Ruedas, M.E.; Martin-Dupont, C. [Uricolytic therapy. Value of urate oxidase in the treatment of hyperuricaemia] Nouvelle Presse Médicale 1975, 4, 1109-1112 (in French).
32. De Bont, J.M.; Pieters, R. Management of hyperuricaemia with rasburicase: review. Nucleosides, Nucleotides and Nucleic Acids 2003, 23, 1431-1440.
33. Vogt, B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrology Dialysis Transplantation 2005, 20, 431-433.
34. Johnson, R.J.; Kivlighn, S.D.; Kim, Y.-G.; Suga, S.; Fogo, A. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. American Journal of Kidney Diseases 1999, 33, 225-234.
35. Johnson, R.J.; Tuttle, K.R. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. Hypertension 2001, 35, E10.
36. Waring, W.S.; Webb, D.J.; Maxwell, S.R.J. Uric acid as a risk for cardiovascular disease. Quarterly Journal of Medicine 2000, 93, 707-713.
37. Messerli, F.H.; Frohlich, E.D.; Dreslinski, G.R.; Suraez, D.H.; Aristomuno, G.G. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. American Journal of Medicine 1980, 93, 817-821.
38. Muscelli, E.; Natali, A.; Bianchi, S.; Bigazzi, R.; Glavan, A.Q.; Sironi, A.M.; Frascerra, S.; Ciociaro, D.; Ferriannini, E. Effect of insulin on renal sodium and uric acid handling in essential hypertension. American Journal of Hypertension 1996, 9, 746-352.
39. Quinones, G.A.; et al. Effect of insulin on uric acid excretion in humans. American Journal of Physiology 1995, 268, E1-E5.
40. Facchini, F.; Chen, Y.-D.; Hollenbeck, C.B.; Reaven, G.M. Relationship between resistance to insulin-mediated glucose concentration uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266, 3008-3011.
41. Mazzali, M.; Kanellis, J.; Han, L.; Feng, L.; Xia, Y.Y.; Chen, Q.; Kang, D.H.; Gordon, K.L.; Wtabnabe, S.; Nakagawa, T.; Lan, H.Y.; Johnson, R.J. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood-pressure independent mechanism. American Journal of Physiology 2002, F991-F997.
42. Rao, G.N.; Corson, M.A.; Berk, B.C. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain. Journal of Biological Chemistry 1991, 266, 8604-8608.
43. Kang, D.-H.; Nakgawa, T.; Feng, L.; et al. A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002, 13, 2888-2997.
44. Sanchez-Lozada, L.G.; Tapia, E.; Santamaria, J.; Avila Casado, C.; Soto, V.; Nepomuceno, T.; Rodriguez-Iturbe, B. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney International 2005, 67, 237-247.
45. Kang, D.-H.; Nakagawa, T. Uric acid and chronic renal disease: possible implication of hyperuricemia in progression of renal disease. Seminars in Nephrology 2005, 25, 43-49.
46. McBride, M.B.; et al. Presymtomatic detection of familial juvenile hyperuricaemic nephropathy in children. Pediatric Nephrology 1998, 12, 359-364.
47. Syrjanen, J.; Mustonen, J.; Pasternack, A. Hypertriglyceridemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrology Dialysis Transplantation 2000, 15, 34-42.
48. Ohno, I.; Hosya, T.; Gomi, H.; Ichida, K.; Okabe, H.; Hikita, M. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001, 87, 333-339.
49. Gerhardt, U.; Grobe Huttmann, M.; Hohage, H. Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant patients. Clinical Transplantation 1999, 13, 375-379.
50. Fessel, W.J. Renal outcomes of gout and hyperuricemia. American Journal of Medicine 1979, 67, 74-82.
51. Rosenfeld, J.B. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Advances in Experimental Medicine & Biology 1974, 41, 581-596.
52. Gibson, T.; Rodgers, V.; Potter, C.; Simmonds, H.A. Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases 1982, 41, 59-65.
53. Perez-Ruiz, F.; Calobozo, M.; Herrero-Beites, A.M.; Garcia-Erauskin, G.; Pijoan, J.I. Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000, 86, 287-291.
54. Fairbanks, L.; Cameron, J.S.; Venkat Raman, G.; Rigden, S.P.; Rees, L.; Van't Hoff, W.; Mansell, M.; Pattison, J.; Goldsmith, D.J.; Simmonds, H.A. Early treatment with allopurinol in familial juvenile hyperuricaemic nephropathy (FJHN) ameliorates the long-term progression of the renal disease. Quarterly Journal of Medicine 2002, 95, 597-607.
55. Miranda, M.E.; Puig, J.G.; Mateos, F.A.; Herranz, I.; Martinez Ara, J.; Berrocal, T.; Proieto, C.; Picazo, M.L. The influence of allopurinol on renal deterioration in familial nephropathy. Advances in Experimental Medicine and Biology 1994, 370, 61-64.